Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Kyverna Therapeutics is expected to report Q4 2025 results before the market opens on April 1, with analysts forecasting a loss of ($0.80) per share and an earnings call scheduled for April 3 at 4:00 PM ET.
• Shares opened at $7.64 (down 3.2%) with a market cap of about $335M, a negative P/E (-2.05) and a 52‑week range of $1.78–$13.67, reflecting significant volatility around current levels.
• Analyst and institutional sentiment is mixed: the stock has an average rating of Moderate Buy (four Buys, one Sell) and an average target of $28.67, while about 18% is owned by institutions and some firms (Wells Fargo, Morgan Stanley) have set targets as high as $33; the company is a clinical‑stage biotech developing an allogeneic Treg candidate for ulcerative colitis.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) will likely be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Kyverna Therapeutics Trading Down 3.2%

Shares of NASDAQ KYTX opened at $7.64 on Wednesday. The stock has a fifty day simple moving average of $8.34 and a two-hundred day simple moving average of $7.55. Kyverna Therapeutics has a 1-year low of $1.78 and a 1-year high of $13.67. The firm has a market cap of $334.63 million, a price-to-earnings ratio of -2.05 and a beta of 3.32.

Hedge Funds Weigh In On Kyverna Therapeutics

Several hedge funds have recently made changes to their positions in KYTX. Public Employees Retirement System of Ohio purchased a new stake in Kyverna Therapeutics during the 3rd quarter worth about $28,000. Qube Research & Technologies Ltd purchased a new position in Kyverna Therapeutics during the 2nd quarter valued at about $43,000. Rhumbline Advisers grew its holdings in Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock valued at $61,000 after buying an additional 5,694 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Kyverna Therapeutics during the third quarter valued at about $77,000. Finally, Bank of America Corp DE lifted its holdings in shares of Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock worth $81,000 after buying an additional 6,400 shares in the last quarter. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen cut Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Wells Fargo & Company boosted their price objective on Kyverna Therapeutics from $31.00 to $33.00 and gave the company an "overweight" rating in a research note on Tuesday, December 16th. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $28.67.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.